Peter Savas

List of Publications by Year in descending order

43 papers	7,004 citations	172457 29 h-index	243625 44 g-index
45 all docs	45 docs citations	45 times ranked	12259 citing authors

#	Article	IF	Citations
1	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines, 2022, 10, 821.	3.2	5
2	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discovery, 2022, 12, 2058-2073.	9.4	16
3	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 613-620.	2.3	0
4	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research, 2021, 27, 2159-2167.	7.0	9
5	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. Breast Cancer Research and Treatment, 2021, 189, 599-606.	2.5	11
6	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 25-31.	2.0	12
7	Metastatic Breast Cancer: TIL it is Too Late. Clinical Cancer Research, 2020, 26, 526-528.	7.0	11
8	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 101, 104516.	1.5	17
9	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast, 2020, 49, 55-62.	2.2	49
10	Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology, 2020, 31, 1359-1365.	1.2	5
11	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	27.8	221
12	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	5.2	90
13	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
14	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology, 2020, 17, 341-348.	27.6	159
15	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	7.0	355
16	Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. Annals of Oncology, 2019, 30, 1638-1646.	1.2	25
17	Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2â€positive metastatic breast cancer: An Australian case series. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 377-382.	1.1	2
18	Molecular comparison of interval and screenâ€detected breast cancers. Journal of Pathology, 2019, 248, 243-252.	4.5	15

#	Article	IF	Citations
19	The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Annals of Oncology, 2018, 29, 2240-2246.	1.2	113
20	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
21	Checkpoint blockade in the treatment of breast cancer: current status and future directions. British Journal of Cancer, 2018, 119, 4-11.	6.4	82
22	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Seminars in Cancer Biology, 2018, 52, 151-157.	9.6	108
23	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptorâ€“Positive, HER2-Negative Early Breast Cancer. JAMA Oncology, 2018, 4, 1335.	7.1	36
24	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993.	30.7	689
25	Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer. Science Translational Medicine, 2017, 9, .	12.4	227
26	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathology, 2017, 30, 952-963.	5.5	50
27	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncology, The, 2017, 18, 52-62.	10.7	225
28	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology, 2017, 49, 141-155.	0.6	112
29	Combined CDK4/6 and PI3KÎ± Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 6340-6352.	0.9	163
30	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	4.3	530
31	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	4.3	469
32	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology, The, 2017, 18, 1009-1021.	10.7	716
33	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Frontiers in Oncology, 2017, 7, 156.	2.8	87
34	Novel Targeted Agents and Immunotherapy in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 65-75.	3.8	8
35	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Annals of Oncology, 2016, 27, 1860-1866.	1.2	45
36	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66

#	Article	IF	Citations
37	The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250.	2.2	194
38	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241.	27.6	679
39	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428
40	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program â€œCASCADEâ€• PLoS Medicine, 2016, 13, e1002204.	8.4	119
41	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. JAMA Oncology, 2015, 1, 448.	7.1	482
42	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	5.5	177
43	Oncogene addiction and immunity. Current Opinion in Oncology, 2014, 26, 562-567.	2.4	19